Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type0 e5 B2 e% X4 \7 \ W4 S9 N
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * c& S% T. j7 `/ E# \4 y
+ Author Affiliations7 S# s$ W9 }% _6 Y- Q
% [/ d0 k6 u6 c3 y
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . G6 s# \$ u# y
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) M8 j1 J+ z8 @
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 h9 r3 y6 g! s$ t; A4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan + ~0 U6 t( j6 [8 ^
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
* R1 a8 t! m4 V d6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
& D! q$ @# q6 ~6 m+ {& [" m7Kinki University School of Medicine, Osaka 589-8511, Japan ( P: Z4 h( c2 C2 ?5 O3 k) ^
8Izumi Municipal Hospital, Osaka 594-0071, Japan
; A' h1 d* u# P9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan e& l* t) T8 U/ U4 F
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
- \2 G. o' X- V) u# t. ~! H! pAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. , k: K+ e! j4 n1 q
/ {. A9 H$ [4 z5 K( }# n |